Manufacturers of analytical instruments, laboratory automation platforms, and life sciences tools shipping to Japanese universities, pharmaceutical companies, contract research organisations (CROs), and national research institutes (国立研究開発法人) face a compliance problem that is more layered than most Japan import engagements. The instruments themselves, a mass spectrometer, a next-generation sequencer, a flow cytometer, can fall on either side of a product regulatory classification boundary that fundamentally changes the import structure required. And the destination institutions, particularly national research institutes and public universities, carry consumption tax characteristics that make the choice of Importer of Record structure a direct financial question, not merely a procedural one. The most expensive mistakes in this sector come from designing the IOR structure before resolving the product classification and the end-user tax position. This post addresses both.
The Classification Fork: Laboratory Equipment or Medical Device?
The single most consequential determination for any lab instrument import into Japan is whether the product is a medical device (医療機器) regulated under the Pharmaceutical and Medical Device Act (薬機法, also referred to as the PMD Act). This classification is not decided by the product's technical design alone. It is decided by intended use.
A PCR machine used in a research laboratory for gene expression analysis is laboratory equipment. The same physical instrument, when placed on the market for clinical diagnostic purposes, can be a regulated medical device subject to PMD Act approval, certification, and Marketing Authorization Holder (製造販売業者) requirements. The same applies to imaging systems, cell analysers, and a range of instruments that straddle research and clinical applications.
This intended-use determination must happen before the IOR structure is designed, for two reasons.
First, Class III and Class IV medical devices under the PMD Act require Ministry of Health, Labour and Welfare (厚生労働省, MHLW) pre-market approval, with the Pharmaceuticals and Medical Devices Agency (医薬品医療機器総合機構, PMDA) conducting the technical review. Importing such a device for commercial purposes without the corresponding approval in place is a regulatory violation regardless of how the customs declaration is structured. An IOR appointment resolves the customs import question; it does not create market authorization.
Second, Class III and Class IV medical device IOR engagements require Director-level review before Aplash can commit to scope. The product classification governs the compliance depth of the engagement.
For research use instruments that sit clearly outside the PMD Act scope, the import structure proceeds through standard IOR or Attorney for Customs Procedures (税関事務管理人, ACP) channels. For instruments where the intended use is ambiguous or dual (research and clinical), the classification must be resolved with Japan regulatory counsel before the first shipment is arranged.
How the October 2023 IOR Reform Broke Common Lab Equipment Arrangements
Before October 2023, a widely used informal arrangement in the laboratory equipment sector involved research institutes or CROs appearing on Japanese import declarations for instruments they did not yet legally own. Evaluation units shipped on consignment, demonstration equipment, and instruments delivered under deferred-payment or trial-purchase contracts were routinely cleared under the end institution's name, even though title had not transferred and the institution had not paid for the goods.
Japan Customs' clarification in October 2023 addressed this directly. The Customs Act (関税法) requires that the declared importer hold genuine legal rights, specifically disposition rights (処分権限), over the goods at the time the import declaration is filed. An institution appearing as importer for goods it does not yet own, has not paid for, and over which it holds no independent title fails this test.
For laboratory equipment manufacturers, the practical consequence is significant. Evaluation units, demo equipment, and instruments shipped under conditional sale or rental arrangements can no longer be cleared under the Japanese institution's name unless that institution genuinely holds disposition rights at the time of clearance. Manufacturers that have not reviewed their Japan import structure since October 2023 should treat this as a priority.
Two Structures That Work in the Lab Equipment Context
Structure A: Aplash as IOR (Buy-and-Sell)
Under this structure, Aplash is the legal importer named on the import declaration. Aplash purchases the instrument from the overseas manufacturer under a back-to-back purchase agreement, takes title before the import declaration is filed, clears customs in Aplash's name, pays customs duties and import Japanese Consumption Tax (JCT / 消費税), and re-sells the goods to the Japan-side recipient under a separate re-sale agreement. Aplash issues a Qualified Invoice (適格請求書) under the Qualified Invoice System (インボイス制度) to the Japan buyer.
This structure is directly suited to the most common problem cases in lab equipment sales:
(a) Evaluation or demonstration units shipped before a formal purchase commitment, where the research institution cannot legitimately appear as importer because no purchase has occurred.
(b) Consignment or deferred-payment deliveries where title has not transferred at the time of import.
(c) First-time Japan shipments where the manufacturer has no established Japan customs registration and no ongoing import volume that would justify ACP infrastructure.
(d) Shipments to research institutions or public universities that are not set up to act as the declared importer and prefer to receive goods through a defined commercial re-sale from a Japan-based entity.
The buy-and-sell structure is substantive, not nominal. Aplash holds genuine title between purchase and re-sale. Name-lending (名義貸し) without commercial substance is prohibited under the Customs Act and is not what this structure involves.
Structure B: Manufacturer as IOR via Attorney for Customs Procedures (税関事務管理人)
Under this structure, the overseas manufacturer is the legal importer named on the import declaration. Aplash acts as the Attorney for Customs Procedures under Article 95 of the Customs Act (関税法), serving as the manufacturer's procedural representative before Japan Customs. This is available because the manufacturer has no Japan address or resident presence.
This structure additionally requires, before the first shipment:
(a) Registration of the overseas manufacturer under Japan's Qualified Invoice System (インボイス制度) as a Qualified Invoice Issuer (適格請求書発行事業者).
(b) Appointment of a Tax Representative (納税管理人) to handle JCT obligations in Japan on the manufacturer's behalf.
Structure B is well-suited to manufacturers with recurring shipments to multiple Japanese research customers, where maintaining direct importer status simplifies the commercial invoice chain and where the manufacturer wants to control JCT recovery directly without the buy-and-sell layer that Structure A requires. The administrative setup cost of Qualified Invoice Issuer registration and Tax Representative appointment is justified when Japan import volumes are consistent and multi-customer.
The two structures are legally distinct and are not interchangeable alternatives. The choice follows from who holds genuine disposition rights over the goods at the point of import and what the commercial arrangement with the Japan-side institution requires.
JCT and Japanese Research Institutions: Why the End-User Tax Position Matters
At Japan's 10% JCT rate applied to the CIF (cost, insurance, freight) value plus applicable customs duties, the import JCT on a laboratory instrument shipment of any meaningful scale is a significant cash flow item. Whether that JCT is recoverable, and by whom, depends on the registered tax status of the Japan-side entity.
Most private Japanese companies, including private pharmaceutical companies and private CROs, are registered JCT taxable businesses (消費税課税事業者). They can claim JCT input credit through the Qualified Invoice System and recover import JCT through their regular JCT return cycle.
Public universities and many national research institutes occupy a different position. A significant number of Japanese public universities and government-affiliated research bodies are not registered as JCT taxable businesses, or their taxable and non-taxable activities are partially separated in ways that limit JCT input credit eligibility. When the Japan-side recipient cannot claim JCT input credit, the import JCT paid at customs does not flow back through the supply chain. It becomes a permanent cost embedded in the landed price of the instrument.
This has a direct consequence for IOR structure design:
(a) If the Japan institution cannot recover JCT, then Aplash acting as IOR (Structure A) and passing through JCT on the re-sale invoice does not create a tax advantage for that institution. The JCT cost will be reflected in the commercial price regardless of structure. The IOR structure is still required to satisfy the disposition-rights requirement, but the JCT recovery rationale that applies to private-sector buyers does not apply here in the same way.
(b) If the overseas manufacturer uses the ACP structure (Structure B) and issues Qualified Invoices directly, but the Japan institution cannot use them to claim credit, the registration effort for Qualified Invoice Issuer status is still valuable for other Japan customers in the same programme but provides less immediate benefit for this specific end-user.
(c) In either case, the commercial invoice and re-sale price must be structured to reflect the JCT burden accurately. Understating the landed cost because JCT is assumed to be recoverable, when the end-user cannot recover it, creates a pricing error that surfaces at invoice reconciliation.
Manufacturers selling to a mix of private and public institutions in Japan should map the JCT recovery position of each customer class before standardising on a single IOR structure for the programme.
Temporary Importation for Demonstration and Evaluation Units
Not every instrument shipped to Japan for laboratory demonstration or evaluation needs to be formally imported and then re-exported. Japan's temporary importation framework offers a legitimate alternative for genuine demonstration or trial use, subject to conditions.
ATA Carnet (ATA一時輸入通関手帳). For instruments brought to Japan for exhibition, demonstration, or professional use by the manufacturer's own personnel, an ATA Carnet issued by the overseas chamber of commerce can facilitate temporary entry without payment of duties or JCT. The carnet must be endorsed by Japan Customs at the port of entry and at re-export. Goods must leave Japan within the validity period of the carnet. A carnet does not permit transfer of the instrument to a Japan-based third party for their own use.
Temporary importation bond (輸入担保金). Where ATA Carnet is not appropriate or available, Japan Customs allows temporary importation against a security deposit covering the duties and taxes that would apply if the goods were not re-exported. The deposit is released on re-export confirmation.
When temporary importation does not work. Temporary importation procedures are designed for goods that will leave Japan. If the commercial intention is to leave the instrument with the Japanese institution for extended evaluation, with the possibility of a subsequent sale, the temporary import framework is not the right approach: the goods may not remain in Japan under a temporary status if the re-export intention is not genuine. In that scenario, a formal import via Structure A or Structure B, followed by formal re-export if the evaluation does not lead to a sale, is the correct path. Attempting to use temporary importation for what is functionally a trial-sale arrangement creates customs compliance exposure.
HS Classification for Laboratory and Scientific Equipment
Japan's tariff schedule organises laboratory and scientific equipment across several chapters, and the correct classification has a material effect on the applicable customs duty rate.
Chapter 90 covers optical, measuring, precision, and medical instruments. Most analytical and measuring instruments used in research and life sciences fall here. Examples include instruments for measuring physical and chemical properties (heading 9027), oscilloscopes (heading 9030), and mass spectrometers. Chapter 90 instruments typically attract low duty rates, and many specific headings are duty-free under Japan's general tariff schedule or under applicable economic partnership agreement (EPA) preferential rates.
Chapter 84 covers machinery and mechanical appliances. Laboratory equipment with a primary mechanical function, including centrifuges (heading 8421), laboratory freeze-dryers, and certain sterilisation equipment, is classified here rather than in Chapter 90.
Chapter 85 covers electrical machinery and equipment. Laboratory instruments whose principal character is electrical rather than measuring or optical, including certain laboratory power supplies, signal generators, and electronic test instruments, may fall under Chapter 85 headings.
Advance ruling (事前教示) for complex multi-component systems. A high-throughput sequencer, a combined liquid chromatography and mass spectrometry system, or a modular laboratory automation platform is not always classifiable from the face of a commercial invoice. When a system comprises multiple components that could individually fall under different chapter headings, or where the primary function is not immediately obvious from the product description, an advance ruling (事前教示) from Japan Customs provides a binding classification determination before the first shipment. The advance ruling is reusable for subsequent shipments of the same product configuration. For high-value instruments where even a small duty rate difference across headings produces a meaningful cost variance, the advance ruling eliminates classification risk at clearance.
Clinical Trial Materials: A Separate Compliance Layer
Foreign pharmaceutical and biotechnology companies importing clinical trial materials, investigational drugs, or biologics for Phase I, II, or III trials in Japan face requirements that sit outside the standard IOR process entirely.
Imports of investigational medicinal products for clinical trials in Japan are subject to notification requirements under the Pharmaceutical and Medical Device Act (薬機法) and the oversight of the PMDA. The regulatory framework includes specific provisions on quality, labelling, and the protocol under which the import is authorised. GMP (Good Manufacturing Practice / 製造管理および品質管理基準) compliance of the manufacturing facility is a precondition for import.
The IOR structure for clinical trial material imports is determined within this separate regulatory framework. An IOR appointment handles the customs declaration layer, but the broader import authorisation and PMDA notification process must be addressed in parallel with Japan regulatory counsel and the sponsor's clinical affairs team. Manufacturers planning clinical trial imports to Japan should engage regulatory counsel with PMDA experience as the primary adviser, with the IOR structure determined in coordination with that advice.
Common Structural Mistakes to Avoid
Designing the IOR structure before confirming the PMD Act classification. If the instrument is a regulated medical device, the product regulatory pathway must be in place or planned before the customs import structure is finalised. The reverse order creates compliance exposure that cannot be cured retroactively.
Using the Japanese research institute as IOR for evaluation units. After October 2023, this arrangement fails the disposition-rights test where the institution does not hold genuine title. Structure the evaluation shipment as a formal IOR import through Aplash if the institution is not ready to purchase.
Assuming all research institutions can recover JCT. Before standardising JCT pass-through terms in the re-sale invoice, confirm the tax registration status of each Japan-side customer. Public universities and national research institutes may not be able to claim input credit.
Treating ATA Carnet as a substitute for formal import for extended evaluations. Temporary importation requires genuine re-export intention. If the instrument may remain with the Japanese institution after the evaluation period, a formal import is required from the outset.
Filing without an advance ruling for novel multi-component systems. For instruments that span multiple HS chapters or where the primary function is not self-evident, an advance ruling prevents classification disputes at clearance on high-value shipments.
This article is informational only and does not constitute legal, tax, or regulatory advice. Consult a qualified advisor before acting on the content. Last updated: June 2026.